Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of dapirolizumab pegol in systemic lupus erythematosus
jRCT2041260165Not yet recruiting
- Sponsor
- UCB
- Start
- Nov 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Open-label, single-arm trial of dapirolizumab pegol in systemic lupus erythematosus (SLE), sponsored by UCB. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious treatment-emergent adverse events and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2041260165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260165.